Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study

[Figure: see text]

Detalles Bibliográficos
Autores principales: Naderi-Azad, Sheida, Sickandar, Faisal, Pezo, Rossanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362262/
https://www.ncbi.nlm.nih.gov/pubmed/34409348
http://dx.doi.org/10.1016/j.jdin.2020.10.005
_version_ 1783738126833811456
author Naderi-Azad, Sheida
Sickandar, Faisal
Pezo, Rossanna C.
author_facet Naderi-Azad, Sheida
Sickandar, Faisal
Pezo, Rossanna C.
author_sort Naderi-Azad, Sheida
collection PubMed
description [Figure: see text]
format Online
Article
Text
id pubmed-8362262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83622622021-08-17 Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study Naderi-Azad, Sheida Sickandar, Faisal Pezo, Rossanna C. JAAD Int Letter [Figure: see text] Elsevier 2020-11-30 /pmc/articles/PMC8362262/ /pubmed/34409348 http://dx.doi.org/10.1016/j.jdin.2020.10.005 Text en © 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter
Naderi-Azad, Sheida
Sickandar, Faisal
Pezo, Rossanna C.
Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
title Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
title_full Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
title_fullStr Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
title_full_unstemmed Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
title_short Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
title_sort cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic t-lymphocyte–associated protein 4 therapy: a retrospective cohort study
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362262/
https://www.ncbi.nlm.nih.gov/pubmed/34409348
http://dx.doi.org/10.1016/j.jdin.2020.10.005
work_keys_str_mv AT naderiazadsheida cutaneousimmunerelatedadverseeventsinpatientswithmetastaticmelanomaonantiprogrammedcelldeathprotein1andanticytotoxictlymphocyteassociatedprotein4therapyaretrospectivecohortstudy
AT sickandarfaisal cutaneousimmunerelatedadverseeventsinpatientswithmetastaticmelanomaonantiprogrammedcelldeathprotein1andanticytotoxictlymphocyteassociatedprotein4therapyaretrospectivecohortstudy
AT pezorossannac cutaneousimmunerelatedadverseeventsinpatientswithmetastaticmelanomaonantiprogrammedcelldeathprotein1andanticytotoxictlymphocyteassociatedprotein4therapyaretrospectivecohortstudy

Ejemplares similares